Vesting of RSUs and PDMR Dealing

MaxCyte, Inc.

26 March 2025

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Vesting of RSUs and PDMR Dealing

Rockville, Maryland - 26 March 2025: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, announces that on 18 March 2025, as per a filing lodged with the U.S. Securities and Exchange Commission, that XXX,XXX shares of previously granted restricted stock units ("RSUs") vested to Douglas Swirsky, Chief Financial Officer of the Company ("Vesting").   Contemporaneously, 6,939 of the newly vested shares were sold to cover withholding tax due upon the vesting.  Such "sale to cover" was automatically effected to satisfy withholding tax liabilities and does not represent a discretionary trade by Mr. Swirsky. The 20,313 new shares of Common Stock were issued pursuant to the Company's existing block admission facility and were sold by Mr. Swirsky at a price range between $3.140 and $3.215 per Common Stock ("Sale"). The sold shares represent approximately 2.2% of Mr. Swirsky's total equity and option holdings in the Company's stock capital, respectively.

Following the Vesting and Sale, Mr. Swirsky holds 13,374 shares of Common Stock representing 2.2% of the issued stock capital of the Company. Mr. Swirsky holds a further 725,000 options over Common Stock, 98,437 RSUs, and 68,750 Performance Stock Units.

The information in the tables below is provided in accordance with the requirements of the UK Market Abuse Regulation.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	[phone] [e-mail]
Nominated Adviser and Joint Corporate Broker Panmure Liberum Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	[phone]
UK IR Adviser ICR Healthcre Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Douglas Swirsky
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common stock of $0.01 each
	Identification code	US57777K1060
b)	Nature of the transaction	Acquisition of common stock following vesting of RSUs
c)	Price(s) and volume(s)		RSUs:
			Exercise Price(s)	Volume(s)
			N/A	20,313
d)	Aggregated information
	- Aggregated volume	20,313
	- Price	N/A
e)	Date of the transaction	17 March, 2025
f)	Place of the transaction	US Stock Exchange, Nasdaq

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Douglas Swirsky
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common stock of $0.01 each
	Identification code	US57777K1060
b)	Nature of the transaction	Sale of common stock to satisfy withholding tax liabilities as a condition of vesting of RSUs
c)	Price(s) and volume(s)
		Price(s)	Volume
		$3.1400	153
		$3.1450	30
		$3.1500	427
		$3.1550	74
		$3.1600	941
		$3.1650	49
		$3.1700	1676
		$3.1750	37
		$3.1800	904
		$3.1850	103
		$3.1900	902
		$3.1950	62
		$3.2000	497
		$3.2050	166
		$3.2100	664
		$3.2150	254
d)	Aggregated information
	- Aggregated volume	6,939
	- Price	$3.1793
e)	Date of the transaction	18 March, 2025
f)	Place of the transaction	US Stock Exchange, Nasdaq

 

END